The US FDA has approved depemokimab as an add-on maintenance therapy for individuals aged 12 years or older with severe asthma, according to a press release from manufacturer GlaxoSmithKline.
Burlington Free Press on MSN
Canadian wildfire smoke made asthma worse for Vermont kids, says UVM
Asthma symptoms worsened in children in Vermont and upstate New York exposed to smoke from Canadian wildfires, according to a recent study by UVM.
India Today on MSNOpinion
Absence of data isn't absence of harm: Doctor pushes back at govt's no data claim
Calling AQI–lung damage 'not proven' reflects missing long-term Indian studies, not absence of harm, a senior pulmonologist ...
The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback